About Us
Portfolio
Portfolio
Portfolio
Praxgen has over 40 products under development at various stages that have been and will be filed with the FDA and Chinese FDA.
About Us
Portfolio
Portfolio
Praxgen Pharmaceuticals, formerly SunGen Pharma, was founded in 2016 by a team of distinguished pharma executives. The name Praxgen reflects our commitment to a practical and accessible path to patient health through high-quality generic pharmaceuticals.
Portfolio
In the News
SunGen Pharma Rebrands as Praxgen Pharmaceuticals
Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)
Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)
We are excited to announce that SunGen Pharma has rebranded as Praxgen Pharmaceuticals!
Over the past five years, SunGen focused on actively building a company that can both develop a wide range of drug products while maintaining flexibility and dedication to R&D fundamentals. SunGen is not and has never been affiliated with SUN PHARMA® and/or Sun Pharmaceutical Industries, Ltd.
Our new name, Praxgen Pharmaceuticals, reflects our commitment to patient health. The path to health should be practical and accessible to everyone, and we aim to help achieve that through high-quality generic pharmaceuticals.
Amidst this thrilling name change, Praxgen’s quality remains constant. We will continue to focus on developing exemplary prescription drugs for introduction into the market to bring accessibility to the masses.
Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)
Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)
Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)
Oakrum and SunGen announced the U.S. launch and commercial shipment of a generic version of Medrol® (Methylprednisolone) in 4 mg tablets. It is anticipated that the product will serve the retail market with annual sales in the U.S. exceeding $110 million in the aggregate for the 12-month period ending December 31, 2018 according to available data from IQVIA.
SunGen Pharma Receives Seventh ANDA Approval from US FDA
Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)
SunGen Pharma Receives Seventh ANDA Approval from US FDA
The seventh approved ANDA is for Fosaprepitant for Injection 150mg/vial. This drug product is used for treatment of cyclic vomiting syndrome and late-stage, chemotherapy-induced vomiting. This is a sub-blockbuster product of over $350M US market size for 2018 according to IQVIA. Emend®’s patent expired on Sep 4th and SunGen obtained its ANDA approval on Sep 5th, which includes it in the first wave of all generic approvals for Emend®.